newsfilter
← Latest News
GlobeNewswire·

Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference in London

  • Corvus Pharmaceuticals will hold one-on-one meetings and present a corporate overview at the 2026 Jefferies Global Healthcare Conference in London.
  • The presentation is scheduled for Monday, November 16, 2026, at 2:30 PM GMT (9:30 am ET / 6:30 am PT).
  • A live webcast of the event will be available 90 days post-event via the investor relations section of the Corvus website.
  • Corvus is developing soquelitinib, an oral ITK inhibitor, in a Phase 3 trial for relapsed/refractory peripheral T cell lymphoma.
  • Soquelitinib is also being evaluated in a Phase 2 trial for atopic dermatitis & a Phase 1b trial for hidradenitis suppurativa.
  • The company is developing other clinical-stage candidates for various cancer indications.
  • Investor contact is Zack Kubow, Vice President of Investor Relations & Corporate Communications.
  • Media inquiries should be directed to Julia Stern of Real Chemistry.